{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/dyspepsia-proven-functional/","result":{"data":{"firstChapter":{"id":"8b6fdb09-e6f3-5061-8539-ae2f57647698","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field bb1bfc18-1956-41c6-8cc8-3480188896e8 --><h1>Dyspepsia - proven functional: Summary</h1><!-- end field bb1bfc18-1956-41c6-8cc8-3480188896e8 -->","htmlStringContent":"<!-- begin item 2219eda5-a8f2-4b31-b41d-4fd3e31286d7 --><!-- begin field aa9dc12f-6517-4a47-955c-38b0f112a6ee --><ul><li>The term 'dyspepsia' is used to describe a complex of upper gastrointestinal tract symptoms which are typically present for four or more weeks, including upper abdominal pain or discomfort, heartburn, acid reflux, nausea and/or vomiting.<ul><li>If symptoms of heartburn and acid regurgitation predominate, then gastro-oesophageal reflux disease (GORD) is the more likely diagnosis.</li></ul></li><li>Functional dyspepsia (also known as non-ulcer dyspepsia) refers to people with dyspepsia symptoms and normal findings on endoscopy (gastric or duodenal ulcer, gastric malignancy, or oesophagitis have been excluded).<ul><li>Functional dyspepsia is the most common diagnosis when endoscopy is performed to investigate dyspepsia symptoms.</li></ul></li><li>Two sub-types of functional dyspepsia have been defined, which can overlap:<ul><li>Epigastric pain syndrome, where intermittent or burning pain is localized to the epigastrium.</li><li>Post-prandial distress syndrome, where there is post-prandial fullness or early satiety.</li></ul></li><li>The cause of functional dyspepsia remains uncertain and is likely to be multifactorial.</li><li>If left untreated, at least 70% of people with functional dyspepsia will have persistent symptoms one year after diagnosis, and the lifetime risk of recurrence is about 50%.</li><li>Initial management of functional dyspepsia includes:<ul><li>Offering advice on lifestyle measures that may improve symptoms.</li><li>Assessing for stress, anxiety, and depression, and managing these appropriately.</li><li>Reviewing and stopping any drugs which may be exacerbating symptoms, if possible and appropriate.</li></ul></li><li>Testing for Helicobacter pylori infection should be arranged if the person's status is not known or uncertain.<ul><li>Ideally a carbon-13 urea breath test or stool antigen test should be used — ensuring the person has not taken a proton pump inhibitor (PPI) in the past 2 weeks, or antibiotics in the past 4 weeks.</li><li>First-line H. pylori eradication therapy should be offered if the person tests positive.</li><li>A low-dose proton pump inhibitor (PPI) or standard-dose histamine (H<sub>2</sub>)-receptor antagonist (H<sub>2</sub>RA) should be offered for 1 month if the person tests negative.</li></ul></li><li>If there are recurrent or refractory symptoms despite initial management:<ul><li>Re-testing for H. pylori infection should not be offered routinely, but may be considered in certain clinical circumstances.</li><li>Second-line H. pylori eradication therapy should be offered if the person tests positive.</li><li>A low-dose PPI or standard-dose H<sub>2</sub>RA should be offered for 1 month if the test is negative or not needed.</li><li>Alternative acid suppression therapy can be considered if there are ongoing symptoms.</li><li>Long-term acid suppression therapy can be considered if there are ongoing symptoms.</li></ul></li><li>People on long-term treatment for functional dyspepsia should be:<ul><li>Offered an annual review.</li><li>Encouraged to step down or stop treatment, if possible and appropriate.</li></ul></li><li>Referral to a gastroenterologist should be considered if:<ul><li>There are refractory or recurrent symptoms despite optimal management in primary care.</li><li>Treatment with a second-line H. pylori eradication regimen has been unsuccessful.</li><li>There are limited antibiotic options for H. pylori eradication therapy.</li></ul></li></ul><!-- end field aa9dc12f-6517-4a47-955c-38b0f112a6ee --><!-- end item 2219eda5-a8f2-4b31-b41d-4fd3e31286d7 -->","topic":{"id":"5cc1cb73-764f-51c5-bc62-44f807111272","topicId":"36754870-050c-4543-8dfe-bee25a1d10bb","topicName":"Dyspepsia - proven functional","slug":"dyspepsia-proven-functional","aliases":[],"chapters":[{"id":"8b6fdb09-e6f3-5061-8539-ae2f57647698","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"63a6aa45-5022-5194-bebc-bd4481b831fe","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"6cdc4376-525a-5e58-8be2-dd0831642d02","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"257ffcf8-d6ac-58d1-b852-f9bb7329f249","slug":"changes","fullItemName":"Changes"},{"id":"d05055eb-ebd0-5056-b860-1ea85daeb311","slug":"update","fullItemName":"Update"}]},{"id":"b6f4608e-164d-578d-8142-8b175799683f","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"bf8575af-2f9b-5729-a628-5efb1ed0411d","slug":"goals","fullItemName":"Goals"},{"id":"761ef9c0-39a0-5dd7-9216-2dc7963b0a6a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"694c1d21-0d63-5dc6-bb90-b5acdbeb64ab","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9244dd4a-0551-5975-b909-6d728dfadcdd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9029a91f-3843-5e59-8544-cb7adfa2c457","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"19b1713f-a518-57e7-a0c1-cdb48d0b4a0d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"e265526e-adb9-5805-aedd-2e2bc77bb54c","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"93b80ba3-9d73-5fc5-8b0e-7a57de8d6107","slug":"definition","fullItemName":"Definition"},{"id":"8f596c75-9a83-5d33-8b9a-4d18a9e24e2e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0a9f461a-38b9-56d1-8511-e41e822e0e8a","slug":"complications","fullItemName":"Complications"},{"id":"e7524b44-b1cf-50d9-806d-bd52695ec307","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a156deba-ce54-58e0-8984-13e20203cd70","slug":"management","fullItemName":"Management","subChapters":[{"id":"ff03390b-be65-558d-83cf-6808e0b84339","slug":"management-of-functional-dyspepsia","fullItemName":"Scenario: Management of functional dyspepsia"}]},{"id":"40a9d515-33a2-5915-b7db-28a3edf79724","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"c3d76d92-046e-5ac3-84fa-c59eff3cd774","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors"},{"id":"8ad244d5-29e6-5577-8efb-eae73fd2faad","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"},{"id":"29d86046-683d-5047-a344-9b0961e8916a","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"891aafa8-13c0-5175-b0ac-580bd4cbe1b8","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"c11610d4-e4be-5dbb-baf5-5414f7bea599","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"a8c93904-08fc-57a4-b238-068ab96b5615","slug":"tetracycline","fullItemName":"Tetracycline"},{"id":"6075addb-8b4a-5e26-9d73-a9cd48dd70f3","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"348b1111-2664-52e1-9fd6-2d26abd69bcb","slug":"bismuth","fullItemName":"Bismuth"}]},{"id":"2d629b23-aa42-5503-980b-2c202de4c387","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"4be75458-608e-5c04-9441-7001ced7fc6d","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"6ad0185f-1607-5a33-9e94-892b09578c17","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6489fce3-cac9-583f-a217-70ba5562de71","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e29927f4-a004-5126-a503-f1045ce72a28","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ca579371-2f3e-59ad-887e-7215f885a62a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"de65b79c-b356-54be-a611-9a871e60c85e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"43271e4f-f094-520d-bd20-f6582fc6ba97","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"5cc1cb73-764f-51c5-bc62-44f807111272","topicId":"36754870-050c-4543-8dfe-bee25a1d10bb","topicName":"Dyspepsia - proven functional","slug":"dyspepsia-proven-functional","aliases":[],"topicSummary":"The term 'dyspepsia' is used to describe a complex of upper gastrointestinal tract symptoms","lastRevised":"Last revised in October 2018","nextPlannedReviewBy":"2022-10-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2022-09","nextPlannedReviewByDisplay":"September 2022","specialities":[{"id":"e4fd15e3-ef70-523f-843c-5270742f518d","name":"Gastrointestinal","slug":"gastrointestinal"}],"chapters":[{"id":"8b6fdb09-e6f3-5061-8539-ae2f57647698","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"63a6aa45-5022-5194-bebc-bd4481b831fe","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"6cdc4376-525a-5e58-8be2-dd0831642d02","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"257ffcf8-d6ac-58d1-b852-f9bb7329f249","slug":"changes","fullItemName":"Changes"},{"id":"d05055eb-ebd0-5056-b860-1ea85daeb311","slug":"update","fullItemName":"Update"}]},{"id":"b6f4608e-164d-578d-8142-8b175799683f","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"bf8575af-2f9b-5729-a628-5efb1ed0411d","slug":"goals","fullItemName":"Goals"},{"id":"761ef9c0-39a0-5dd7-9216-2dc7963b0a6a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"694c1d21-0d63-5dc6-bb90-b5acdbeb64ab","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9244dd4a-0551-5975-b909-6d728dfadcdd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9029a91f-3843-5e59-8544-cb7adfa2c457","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"19b1713f-a518-57e7-a0c1-cdb48d0b4a0d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"e265526e-adb9-5805-aedd-2e2bc77bb54c","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"93b80ba3-9d73-5fc5-8b0e-7a57de8d6107","slug":"definition","fullItemName":"Definition"},{"id":"8f596c75-9a83-5d33-8b9a-4d18a9e24e2e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0a9f461a-38b9-56d1-8511-e41e822e0e8a","slug":"complications","fullItemName":"Complications"},{"id":"e7524b44-b1cf-50d9-806d-bd52695ec307","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a156deba-ce54-58e0-8984-13e20203cd70","slug":"management","fullItemName":"Management","subChapters":[{"id":"ff03390b-be65-558d-83cf-6808e0b84339","slug":"management-of-functional-dyspepsia","fullItemName":"Scenario: Management of functional dyspepsia"}]},{"id":"40a9d515-33a2-5915-b7db-28a3edf79724","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"c3d76d92-046e-5ac3-84fa-c59eff3cd774","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors"},{"id":"8ad244d5-29e6-5577-8efb-eae73fd2faad","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"},{"id":"29d86046-683d-5047-a344-9b0961e8916a","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"891aafa8-13c0-5175-b0ac-580bd4cbe1b8","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"c11610d4-e4be-5dbb-baf5-5414f7bea599","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"a8c93904-08fc-57a4-b238-068ab96b5615","slug":"tetracycline","fullItemName":"Tetracycline"},{"id":"6075addb-8b4a-5e26-9d73-a9cd48dd70f3","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"348b1111-2664-52e1-9fd6-2d26abd69bcb","slug":"bismuth","fullItemName":"Bismuth"}]},{"id":"2d629b23-aa42-5503-980b-2c202de4c387","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"4be75458-608e-5c04-9441-7001ced7fc6d","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"6ad0185f-1607-5a33-9e94-892b09578c17","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6489fce3-cac9-583f-a217-70ba5562de71","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e29927f4-a004-5126-a503-f1045ce72a28","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ca579371-2f3e-59ad-887e-7215f885a62a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"de65b79c-b356-54be-a611-9a871e60c85e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"43271e4f-f094-520d-bd20-f6582fc6ba97","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"5cc1cb73-764f-51c5-bc62-44f807111272"}},"staticQueryHashes":["3666801979"]}